Not only does aspirin prevent the development of gastrointestinal cancer, but it can also multiply the life expectancy of patients with gastrointestinal cancers? A study that included nearly 1,400 patients with gastrointestinal cancers was recently reported at the European Cancer Congress and was initiated by Dr. Martine Frouws of Leiden Medical Center in the Netherlands. The researchers found that taking low-dose aspirin after diagnosis of gastrointestinal cancers significantly prolonged survival in these patients, with a 5-year survival rate of 75 percent compared to 40 percent for those who did not take it. The cancers included in the study were colon (48%), followed by rectum (42.8%), with esophageal cancer coming in third at 10.2%. Currently, more and more medical research is focusing on personalized precision medicine, but the expensive cost and limited indication of the population make the application of personalized treatment encounter difficulties. And this study confirms that aspirin is low cost and low risk, which can have the effect of reducing the incidence of digestive tract tumors and prolonging survival time. Not only can it prevent, but also assist in cancer treatment? Early studies found that aspirin can effectively prevent the occurrence of colon cancer and other diseases; and as an anti-platelet agent, it can effectively prevent and treat ischemic cardiovascular disease and Alzheimer’s disease. And researchers at the Sourasky Medical Center in Tel Aviv, Israel, found that aspirin was actually effective in extending survival time for gastrointestinal cancers as an adjuvant treatment. The appropriate dose and duration of aspirin and the aspirin risk-benefit ratio are not yet clear, but in the field of precision medicine, genetic information and blood and/or urine biomarkers may help screen those patients who will benefit the most while minimizing adverse effects. Aspirin will be of great use in preventing and improving gastrointestinal cancers because of its low price and few side effects. However, not all patients have a clear benefit from taking aspirin, and it will be a significant and meaningful question in the next studies to effectively identify patients who can benefit and thus be treated differently.